The FLOW trial recently showed that treatment with the glucagon-like peptide-1 receptor agonists semaglutide significantly reduced the incidence of clinically important kidney outcomes in patients with type 2 diabetes and CKD, likely through beneficial effects on kidney blood flow, inflammation, and fibrosis as well as effects mediated by improvement of glycemic control. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.